These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34280775)

  • 1. A machine learning-based risk stratification model for ventricular tachycardia and heart failure in hypertrophic cardiomyopathy.
    Smole T; Žunkovič B; Pičulin M; Kokalj E; Robnik-Šikonja M; Kukar M; Fotiadis DI; Pezoulas VC; Tachos NS; Barlocco F; Mazzarotto F; Popović D; Maier L; Velicki L; MacGowan GA; Olivotto I; Filipović N; Jakovljević DG; Bosnić Z
    Comput Biol Med; 2021 Aug; 135():104648. PubMed ID: 34280775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the development of adverse cardiac events in patients with hypertrophic cardiomyopathy using machine learning.
    Kochav SM; Raita Y; Fifer MA; Takayama H; Ginns J; Maurer MS; Reilly MP; Hasegawa K; Shimada YJ
    Int J Cardiol; 2021 Mar; 327():117-124. PubMed ID: 33181159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Ventricular Arrhythmias and Their Predictors by Applying Machine Learning Methods to Electronic Health Records in Patients With Hypertrophic Cardiomyopathy (HCM-VAr-Risk Model).
    Bhattacharya M; Lu DY; Kudchadkar SM; Greenland GV; Lingamaneni P; Corona-Villalobos CP; Guan Y; Marine JE; Olgin JE; Zimmerman S; Abraham TP; Shatkay H; Abraham MR
    Am J Cardiol; 2019 May; 123(10):1681-1689. PubMed ID: 30952382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of ventricular tachyarrhythmia in patients with hypertrophic cardiomyopathy with machine learning-based texture analysis of late gadolinium enhancement cardiac MRI.
    Alis D; Guler A; Yergin M; Asmakutlu O
    Diagn Interv Imaging; 2020 Mar; 101(3):137-146. PubMed ID: 31727603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
    Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
    Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
    Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
    Elliott PM; Sharma S; Varnava A; Poloniecki J; Rowland E; McKenna WJ
    J Am Coll Cardiol; 1999 May; 33(6):1596-601. PubMed ID: 10334430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand.
    Songsirisuk N; Kittipibul V; Methachittiphan N; Charoenattasil V; Zungsontiporn N; Spanuchart I; Buppajarntham S; Mankongpaisarnrung C; Satitthummanid S; Srimahachota S; Chattranukulchai P; Boonyaratavej Songmuang S; Puwanant S
    BMC Cardiovasc Disord; 2019 Jan; 19(1):1. PubMed ID: 30606129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge.
    Weissler-Snir A; Adler A; Williams L; Gruner C; Rakowski H
    Eur Heart J; 2017 Jun; 38(22):1728-1737. PubMed ID: 27371714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease Progression of Hypertrophic Cardiomyopathy: Modeling Using Machine Learning.
    Pičulin M; Smole T; Žunkovič B; Kokalj E; Robnik-Šikonja M; Kukar M; Fotiadis DI; Pezoulas VC; Tachos NS; Barlocco F; Mazzarotto F; Popović D; Maier LS; Velicki L; Olivotto I; MacGowan GA; Jakovljević DG; Filipović N; Bosnić Z
    JMIR Med Inform; 2022 Feb; 10(2):e30483. PubMed ID: 35107432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.
    Lu DY; Pozios I; Haileselassie B; Ventoulis I; Liu H; Sorensen LL; Canepa M; Phillip S; Abraham MR; Abraham TP
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of Prognostic Heart Failure Models in Patients With Nonischemic Cardiomyopathy Undergoing Ventricular Tachycardia Ablation.
    Muser D; Liang JJ; Castro SA; Lanera C; Enriquez A; Kuo L; Magnani S; Birati EY; Lin D; Schaller R; Supple G; Zado E; Garcia FC; Nazarian S; Dixit S; Frankel DS; Callans DJ; Marchlinski FE; Santangeli P
    JACC Clin Electrophysiol; 2019 Jul; 5(7):801-813. PubMed ID: 31320008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.
    Maron MS; Rowin EJ; Wessler BS; Mooney PJ; Fatima A; Patel P; Koethe BC; Romashko M; Link MS; Maron BJ
    JAMA Cardiol; 2019 Jul; 4(7):644-657. PubMed ID: 31116360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
    Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
    Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragmented QRS predicts heart failure progression in patients with hypertrophic cardiomyopathy.
    Nomura A; Konno T; Fujita T; Tanaka Y; Nagata Y; Tsuda T; Hodatsu A; Sakata K; Nakamura H; Kawashiri MA; Fujino N; Yamagishi M; Hayashi K
    Circ J; 2015; 79(1):136-43. PubMed ID: 25381793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Machine Learning-Based Discrimination of Cardiovascular Outcomes in Patients With Hypertrophic Cardiomyopathy.
    Rhee TM; Ko YK; Kim HK; Lee SB; Kim BS; Choi HM; Hwang IC; Park JB; Yoon YE; Kim YJ; Cho GY
    JACC Asia; 2024 May; 4(5):375-386. PubMed ID: 38765660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep learning-derived 12-lead electrocardiogram-based genotype prediction for hypertrophic cardiomyopathy: a pilot study.
    Chen L; Fu G; Jiang C
    Ann Med; 2023 Dec; 55(1):2235564. PubMed ID: 37467172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
    Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
    Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.